The Theatre of Prosperity: Two Healthcare Stocks with a Flourish

by

In the grand comedy of market ventures, the first act finds us amidst a year ripe with spectacle and folly surrounding the stocks of 2025. Yet, as any discerning spectator knows, the choice of which players to endorse is—like a well-timed punchline—as personal as one’s own reflection. One must weigh the propensities for risk, the allure of commerce’s sectors, and the size of one’s wallet, lest the merchant’s mirth turn into tragic farce.

Within this carnival of capital, some treasures shimmer with the promise of doubling their worth—a spectacle truly worth the theatrical stage. Here enters our first act: the curious case of two healthcare enterprises—both having doubled in the span of a mere twelve moons, yet still standing on the verge of further ascent, their banners fluttering in the wind of future prosperity.

1. Hims & Hers, the Before-the-Polished Mirror

Ah, Hims & Hers (HIMS), a brash and braggart player in this market ensemble, who lately boasts a share price that has danced a splendid 200% in just one year, outstripping the modest 18% increase of the venerable S&P 500. This vertical rise, the result of fervent investor applause, owes much to their daring venture into the realm of compounded GLP-1 remedies—those elixirs promising relief from weighty burdens—-fueled by shortages and a dash of entrepreneurial bravado. A veritable feast for the eyes of those who covet swift profits.

Yet, as all actors discover, the script unfolds with irony. The FDA—ever the stern critic—declared the shortage of semaglutide resolved, depriving our company of its most flamboyant act: mass production of compounded medicines. Now, the scène shifts to oral remedies and the more mundane liraglutide, while Novo Nordisk—whose Wegovy and Ozempic have become legends—reluctantly ends its partnership, citing concerns of promotion and sales that, perhaps, risk crossing the boundaries of propriety. One must ask: does the company’s reliance on such fleeting applause portend an encore or a curtain fall?

Loading widget...

Nevertheless, our esteemed company does not find itself solely imprisoned by the weight-loss act. No—its stage broadens into domains of sexual health, dermatology, mental wellness, and primary care, all accessible via the spectacle of online consultations. The revenue, robust at a 110% increase in the first quarter, and with a generous cash cash flow of fifty million dollars, suggests this enterprise holds potential for an encore performance or, at the very least, some favorable audience applause. Moreover, the recent acquisition of Zava, a European digital health platform, hints at ambitions that stretch beyond the borders of mere weight management, into the theaters of the UK, Ireland, France, and Germany, with an eye set on Canada for 2026—an act of expansion worthy of a playwright’s daring.

2. Doximity, the Court of Magicians

The second act introduces us to Doximity, a seeming conjurer of fortunes, which over the past year has seen its shares leap by over 100%. This enterprise is, in truth, a modern sorcerer’s den—an enchanted platform for the medical elite in the United States, where doctors, nurses, and physician assistants congregate and mingle amidst tools of communication, news, and career advancement.

With characteristics rivaling a social network infused with wizardry, Doximity dispenses a curated stream of medical lore and provides the magic of telehealth solutions—virtually turning the consulting room into a stage for consultations. To its users, the service appears free—akin to a noble gift—featuring the Doximity Dialer, secure fax lines, and a curious AI scribe, all paid for not by subscriptions, but by the spellbinding art of advertising and the sale of precious information.

And what of the coin itself? The company’s fiscal performance reveals a Cardiff-like ascent—2025’s revenue, rising 20% to nearly $570 million, and net income that soared by 51%, reaching a quarter-billion dollars—and free cash flow that grew by a magical 50%. In essence, Doximity’s charm lies not merely in its digital allure but in the profitable enchantment of its advertising empire—an industry that, while seemingly trivial, produces a profit that might make the Miser blush with envy. Such strength suggests this company could well encore, keeping the audience enthralled, eager for what encore this modern Bard of Health might deliver.

Read More

2025-08-03 23:13